Result page for
Withdrawn ID 837:
Amprenavir
![837](./images/837.png)
General information:
Withdrawal information:
Withdrawn due to drug safety reasons: | No |
First approved: |
1999 |
First withdrawn: |
2004 |
Last withdrawn: |
2004 |
Side-effects:
Total reported cases (submitted by medical professionals)
with Amprenavir as primary suspect: |
7 |
Reported final outcomes:
Hospitalization (initial or prolonged): |
1 |
Reported side-effects:
Side-effect |
Case number |
LIPASE INCREASED | 1 |
ACANTHOSIS NIGRICANS | 1 |
ASTHENIA | 1 |
BLOOD CHOLESTEROL INCREASED | 1 |
CD4 LYMPHOCYTES DECREASED | 1 |
DEPRESSION | 1 |
HEPATOCELLULAR DAMAGE | 1 |
HYPERGLYCAEMIA | 1 |
INSOMNIA | 1 |
INSULIN RESISTANCE | 1 |
VIRAL LOAD INCREASED | 1 |
LIPODYSTROPHY ACQUIRED | 1 |
MUCOSAL ULCERATION | 1 |
PARAESTHESIA CIRCUMORAL | 1 |
PHARYNX DISCOMFORT | 1 |
PRURITUS | 1 |
RASH | 1 |
RASH MACULO-PAPULAR | 1 |
TOXIC SKIN ERUPTION | 1 |
Filtered ChEMBL targets:
Target UniProtKB ID |
Activity in nm |
Target Name |
Target gene |
P02545 |
631 |
Prelamin-A/C |
LMNA_HUMAN |
P24557 |
6727 |
Thromboxane-A synthase |
THAS_HUMAN |
Toxicity information:
External links: